{"id":"NCT01519700","sponsor":"Sandoz","briefTitle":"Phase III Study Comparing the Efficacy and Safety of EP2006 and Filgrastim","officialTitle":"A Randomized, Double-blind, Parallel-group, Multi-center Phase III Study Comparing the Efficacy and Safety of EP2006 and NeupogenÂ® in Breast Cancer Patients Treated With Myelosuppressive Chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-12","primaryCompletion":"2013-06","completion":"2013-06","firstPosted":"2012-01-27","resultsPosted":"2015-04-07","lastUpdate":"2015-05-06"},"enrollment":218,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Chemotherapy Associated Neutropenia","Breast Cancer"],"interventions":[{"type":"DRUG","name":"EP2006","otherNames":["Filgrastim"]},{"type":"DRUG","name":"Filgrastim","otherNames":[]}],"arms":[{"label":"EP2006","type":"EXPERIMENTAL"},{"label":"Filgrastim","type":"ACTIVE_COMPARATOR"}],"summary":"The study will assess the efficacy of EP2006 compared to Filgrastim with respect to the mean duration of severe neutropenia during treatment with myelosuppressive chemotherapy in breast cancer patients.","primaryOutcome":{"measure":"Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy","timeFrame":"21 days (Cycle 1 of chemotherapy treatment)","effectByArm":[{"arm":"EP2006 + EP2006 & Neupogen","deltaMin":1.17,"sd":1.11},{"arm":"Neupogen + Neupogen & EP2006","deltaMin":1.2,"sd":1.02}],"pValues":[{"comp":"OG000","p":null}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":26,"countries":["Czechia","Hungary","Latvia","Russia","Slovakia","Ukraine"]},"refs":{"pmids":["26122726"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":53},"commonTop":["Alopecia","Nausea","Asthenia","Bone pain","Fatigue"]}}